Lawrence V Rubinstein

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Therapeutic studies
    L V Rubinstein
    Biometric Research Branch, National Cancer Institute, Bethesda, Maryland, USA
    Hematol Oncol Clin North Am 14:849-76, ix. 2000
  2. ncbi Design issues of randomized phase II trials and a proposal for phase II screening trials
    Lawrence V Rubinstein
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 23:7199-206. 2005
  3. ncbi Randomized phase II designs
    Larry Rubinstein
    National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 15:1883-90. 2009
  4. ncbi The statistics of phase 0 trials
    Larry V Rubinstein
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Stat Med 29:1072-6. 2010
  5. ncbi Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
    Lori E Dodd
    Division of Cancer Treatment and Diagnosis, Branches of Biometric Research, Investigational Drug, Cancer Investigations, and Diagnostic Imaging, National Cancer Institute, Rockville, MD 20892, USA
    J Clin Oncol 26:3791-6. 2008
  6. ncbi Dose escalation trial designs based on a molecularly targeted endpoint
    Sally Hunsberger
    Biometrics Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Stat Med 24:2171-81. 2005
  7. ncbi An information-intensive approach to the molecular pharmacology of cancer
    J N Weinstein
    Laboratory of Molecular Pharmacology LMP, Division of Basic Science, National Cancer Institute NCI, National Institutes of Health, Bethesda, MD 20892, USA
    Science 275:343-9. 1997
  8. ncbi Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
    J I Johnson
    Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Br J Cancer 84:1424-31. 2001

Detail Information

Publications8

  1. ncbi Therapeutic studies
    L V Rubinstein
    Biometric Research Branch, National Cancer Institute, Bethesda, Maryland, USA
    Hematol Oncol Clin North Am 14:849-76, ix. 2000
    ..This shared problem gives rise to statistical designs with basic similarities across the three trial types...
  2. ncbi Design issues of randomized phase II trials and a proposal for phase II screening trials
    Lawrence V Rubinstein
    Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 23:7199-206. 2005
    ....
  3. ncbi Randomized phase II designs
    Larry Rubinstein
    National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 15:1883-90. 2009
    ....
  4. ncbi The statistics of phase 0 trials
    Larry V Rubinstein
    Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Stat Med 29:1072-6. 2010
    ..The phase 0 trial promises to become an increasingly important tool for facilitating and speeding the development of new therapeutic agents, particularly in oncology...
  5. ncbi Blinded independent central review of progression-free survival in phase III clinical trials: important design element or unnecessary expense?
    Lori E Dodd
    Division of Cancer Treatment and Diagnosis, Branches of Biometric Research, Investigational Drug, Cancer Investigations, and Diagnostic Imaging, National Cancer Institute, Rockville, MD 20892, USA
    J Clin Oncol 26:3791-6. 2008
    ..When such designs are not practical, BICR is not recommended as a general strategy for reducing bias. However, BICR may be useful as an auditing tool to assess the reliability of marginally positive results...
  6. ncbi Dose escalation trial designs based on a molecularly targeted endpoint
    Sally Hunsberger
    Biometrics Research Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    Stat Med 24:2171-81. 2005
    ..A limited simulation study is performed and the designs are compared with respect to the dose level at the end of escalation and the number of patients treated on study...
  7. ncbi An information-intensive approach to the molecular pharmacology of cancer
    J N Weinstein
    Laboratory of Molecular Pharmacology LMP, Division of Basic Science, National Cancer Institute NCI, National Institutes of Health, Bethesda, MD 20892, USA
    Science 275:343-9. 1997
    ..It remains to be seen how effective this information-intensive strategy will be at generating new clinically active agents...
  8. ncbi Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials
    J I Johnson
    Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
    Br J Cancer 84:1424-31. 2001
    ..0001). Structural parameters of the drugs analysed included compound molecular weight and hydrogen-bonding factors, both of which were found to be predictive of hollow fibre activity...